Fig. 4

SOX3 endogenous expression and its effect on the proliferation, migration, invasion and apoptosis in GSCs, as well as the expression of SOX2OT and TDGF-1. a The SOX3 protein expression levels in normal brain tissues (NBTs), low-grade glioma tissues (WHO I-II) and high-grade glioma tissues (WHO III-IV) are shown. Data are presented as the mean ± SD (n = 3,each group). ^** P < 0.01 vs. NBTs group; ^## P < 0.01 vs. low-grade glioma tissues group. bThe expression level of SOX3 in human astrocytes (HA) and glioblastoma cell lines (U87 and U251). c The expression of SOX3 in glioblastoma cell lines (U87 and U251) and glioblastoma stem cells (GSC-U87, GSC-U251). d CCK-8 assay was used to measure the effect of SOX3 on the proliferation of GSC-U87 and GSC-U251 cells. e The apoptotic percentages of GSC-U87 and GSC-U251 were detected after SOX3 over-expression or knockdown. f Transwell assays was used to measure the effect of SOX3 on cell migration and invasion of GSC-U87 and GSC-U251 cells. Scale bars represent 40 μm. Data are presented as the mean ± SD (n = 5, each group). ^** P < 0.01 vs. SOX3(+)NC group; ^## P < 0.01 vs. SOX3(−)NC group. g Relative expression of SOX2OT with the over-expressing or silencing SOX3. h SOX3 bound to the promoter of SOX2OT in GSC-U87 and GSC-U251 cells. Schematic representation of the human SOX2OT promoter region 3000 bp upstream of the transcription start site (TSS), which was designated as +1. Putative SOX3 binding site was indicated. PCR was conducted with the resulting precipitated DNA. i Weatern blot assay was used to detect the expression of TDGF-1 after SOX3 over-expression or knockdown. j SOX3 bound to the promoter of TDGF-1 in GSC-U87 and GSC-U251 cells. Schematic representation of the human TDGF-1 promoter region 3000 bp upstream of the transcription start site (TSS), which was designated as +1. Putative SOX3 binding site was indicated. PCR was conducted with the resulting precipitated DNA